Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
S.C. Project Management e Formazione, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Naples, Italy.
Drug Des Devel Ther. 2021 Oct 28;15:4447-4454. doi: 10.2147/DDDT.S314666. eCollection 2021.
Coronavirus disease-19 (COVID-19) pandemic is currently ongoing worldwide and causes a lot of deaths in many countries. Although different vaccines for the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection have been developed and are now available, there are no effective antiviral drugs to treat the disease, except for Remdesivir authorized by the US FDA to counteract the emergency. Thus, it can be useful to find alternative therapies based on the employment of natural compounds, with antiviral features, to circumvent SARS-CoV-2 infection. Pre-clinical studies highlighted the antiviral activities of epigallocatechin-3-gallate (EGCG), a catechin primarily found in green tea, against various viruses, including SARS-CoV-2. In this review, we summarize this experimental evidence and highlight the potential use of EGCG as an alternative therapeutic choice for the treatment of SARS-CoV-2 infection.
新型冠状病毒病(COVID-19)大流行目前正在全球范围内持续,在许多国家造成了大量死亡。尽管已经开发出针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的不同疫苗,并且现在已经可用,但除了美国食品和药物管理局授权用于应对紧急情况的瑞德西韦外,没有有效的抗病毒药物来治疗这种疾病。因此,基于使用具有抗病毒特性的天然化合物寻找替代疗法来规避 SARS-CoV-2 感染可能是有用的。临床前研究强调了表没食子儿茶素-3-没食子酸酯(EGCG)的抗病毒活性,EGCG 是一种主要存在于绿茶中的儿茶素,对包括 SARS-CoV-2 在内的多种病毒具有抗病毒作用。在这篇综述中,我们总结了这一实验证据,并强调了 EGCG 作为治疗 SARS-CoV-2 感染的替代治疗选择的潜在用途。